104 related articles for article (PubMed ID: 18084118)
41. Long-term outcomes of children and adolescents who had cerebral palsy with secondary osteoporosis.
Iwasaki T; Nonoda Y; Ishii M
Curr Med Res Opin; 2012 May; 28(5):737-47. PubMed ID: 22126423
[TBL] [Abstract][Full Text] [Related]
42. Cross-sectional evaluation of bone metabolism in men.
Szulc P; Garnero P; Munoz F; Marchand F; Delmas PD
J Bone Miner Res; 2001 Sep; 16(9):1642-50. PubMed ID: 11547833
[TBL] [Abstract][Full Text] [Related]
43. Isosorbide mononitrate increases bone formation and decreases bone resorption in postmenopausal women: a randomized trial.
Jamal SA; Cummings SR; Hawker GA
J Bone Miner Res; 2004 Sep; 19(9):1512-7. PubMed ID: 15312252
[TBL] [Abstract][Full Text] [Related]
44. Serum lipid and bone metabolism effects of Toremifene vs. Letrozole as adjuvant therapy for postmenopausal early breast cancer patients: results of a multicenter open randomized study.
Shien T; Doihara H; Sato N; Anan K; Komaki K; Miyauchi K; Yanagita Y; Fujisawa T; Mitsuyama S; Kanbayashi C; Kusama M; Kimura M; Jinno H; Sano M; Ikeda T
Cancer Chemother Pharmacol; 2018 Feb; 81(2):269-275. PubMed ID: 29196963
[TBL] [Abstract][Full Text] [Related]
45. Effect of walking exercise on bone metabolism in postmenopausal women with osteopenia/osteoporosis.
Yamazaki S; Ichimura S; Iwamoto J; Takeda T; Toyama Y
J Bone Miner Metab; 2004; 22(5):500-8. PubMed ID: 15316873
[TBL] [Abstract][Full Text] [Related]
46. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study.
Garnero P; Sornay-Rendu E; Claustrat B; Delmas PD
J Bone Miner Res; 2000 Aug; 15(8):1526-36. PubMed ID: 10934651
[TBL] [Abstract][Full Text] [Related]
47. Paraoxonase 1 polymorphisms 172T→A and 584A→G modify the association between serum concentrations of the antioxidant lycopene and bone turnover markers and oxidative stress parameters in women 25-70 years of age.
Mackinnon ES; El-Sohemy A; Rao AV; Rao LG
J Nutrigenet Nutrigenomics; 2010; 3(1):1-8. PubMed ID: 20664283
[TBL] [Abstract][Full Text] [Related]
48. Bone mineral density and bone turnover in patients with psoriatic arthritis.
Borman P; Babaoğlu S; Gur G; Bingol S; Bodur H
Clin Rheumatol; 2008 Apr; 27(4):443-7. PubMed ID: 17876648
[TBL] [Abstract][Full Text] [Related]
49. Influence of exercise mode and osteogenic index on bone biomarker responses during short-term physical training.
Lester ME; Urso ML; Evans RK; Pierce JR; Spiering BA; Maresh CM; Hatfield DL; Kraemer WJ; Nindl BC
Bone; 2009 Oct; 45(4):768-76. PubMed ID: 19520194
[TBL] [Abstract][Full Text] [Related]
50. A new approach for evaluating bone turnover in chronic kidney disease.
Tolouian R; Hernandez GT; Chiang WY; Gupta A
Eur J Intern Med; 2010 Jun; 21(3):230-2. PubMed ID: 20493428
[TBL] [Abstract][Full Text] [Related]
51. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.
Alvarez L; Peris P; Guañabens N; Vidal S; Quintó L; Monegal A; Pons F; Ballesta AM; Muñoz-Gómez J
Rheumatology (Oxford); 2004 Jul; 43(7):869-74. PubMed ID: 15054158
[TBL] [Abstract][Full Text] [Related]
52. Monitoring alendronate therapy for osteoporosis.
Braga de Castro Machado A; Hannon R; Eastell R
J Bone Miner Res; 1999 Apr; 14(4):602-8. PubMed ID: 10234582
[TBL] [Abstract][Full Text] [Related]
53. Alfacalcidol reduces accelerated bone turnover in elderly women with osteoporosis.
Shiraki M; Fukuchi M; Kiriyama T; Okamoto S; Ueno T; Sakamoto H; Nagai T
J Bone Miner Metab; 2004; 22(4):352-9. PubMed ID: 15221494
[TBL] [Abstract][Full Text] [Related]
54. Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.
Burshell AL; Möricke R; Correa-Rotter R; Chen P; Warner MR; Dalsky GP; Taylor KA; Krege JH
Bone; 2010 Apr; 46(4):935-9. PubMed ID: 20060081
[TBL] [Abstract][Full Text] [Related]
55. The effect of gonadotropin-releasing hormone agonist on type I collagen C-telopeptide and N-telopeptide: the predictive value of biochemical markers of bone turnover.
Amama EA; Taga M; Minaguchi H
J Clin Endocrinol Metab; 1998 Feb; 83(2):333-8. PubMed ID: 9467536
[TBL] [Abstract][Full Text] [Related]
56. Fish liver oil and propolis as protective natural products against the effect of the anti-epileptic drug valproate on immunological markers of bone formation in rats.
Elwakkad AS; El Elshamy KA; Sibaii H
Epilepsy Res; 2008 Jul; 80(1):47-56. PubMed ID: 18455911
[TBL] [Abstract][Full Text] [Related]
57. Biochemical markers of bone turnover in patients with spinal metastases after resistance training under radiotherapy--a randomized trial.
Rief H; Omlor G; Akbar M; Bruckner T; Rieken S; Förster R; Schlampp I; Welzel T; Bostel T; Roth HJ; Debus J
BMC Cancer; 2016 Mar; 16():231. PubMed ID: 26983672
[TBL] [Abstract][Full Text] [Related]
58. Multiparameter analysis of serum levels of C-telopeptide crosslaps, bone-specific alkaline phosphatase, cathepsin K, osteoprotegerin and receptor activator of nuclear factor κB ligand in the diagnosis of osteoporosis.
Piatek S; Adolf D; Wex T; Halangk W; Klose S; Westphal S; Amthauer H; Winckler S
Maturitas; 2013 Apr; 74(4):363-8. PubMed ID: 23391500
[TBL] [Abstract][Full Text] [Related]
59. [Effects of SERMs on bone health. The evaluation of raloxifene treatment for elderly women with osteoporosis using bone turnover markers].
Hasegawa M; Ichimura S; Satomi K
Clin Calcium; 2010 Mar; 20(3):413-20. PubMed ID: 20190372
[TBL] [Abstract][Full Text] [Related]
60. [Age- and gender-related changes of biochemical markers for bone metabolic turnover].
Dong H; Chen DQ; Wang Y; Li M
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Oct; 27(10):1564-6. PubMed ID: 17959538
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
